Loading
UGT1A1 (UDP-glucuronosyltransferase 1A1) is an enzyme. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. This dossier gathers the 1 product (0 approved), 13 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
UDP-glucuronosyltransferase (UGT) that catalyses phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite's water solubility, thereby facilitating excretion into either the urine or bile. Essential for the elimination and detoxification of drugs, xenobiotics and endogenous compounds. Catalyses the glucuronidation of endogenous oestrogen hormones such as estradiol, estrone and estriol. Involved in the glucuronidation of bilirubin, a degradation product occurring in the normal catabolic pathway that breaks down heme in vertebrates. Involved in the glucuronidation of arachidonic acid (AA) and AA-derived eicosanoids including 15-HETE, 20-HETE, PGB1 and F2-isoprostane (8-iso-PGF2alpha). Involved in the glucuronidation of the phytochemical ferulic acid at the phenolic or the carboxylic acid group. Location: Endoplasmic reticulum membrane; Cytoplasm, perinuclear region (UniProt). Locus 2q37.1 (HGNC).
| Modality | Withdrawn or failed |
|---|---|
| Chemotherapy 1 |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
CAIRO5 NCT02162563 | 3 | Mixed | Initially unresectable colorectal liver metastases, stratified by sidedness and RAS/BRAF status: a doublet plus bevacizumab, FOLFOXIRI plus bevacizumab, or a doublet plus panitumumab, with central resectability review every two months | FOLFOXIRI plus bevacizumab better than a doublet for right-sided or RAS/BRAF-mutant disease; panitumumab no better than bevacizumab for left-sided wild-type disease. | |
TRIBE2 NCT02339116 | 3 | Positive | Untreated metastatic colorectal cancer: upfront FOLFOXIRI plus bevacizumab with reintroduction after progression, against sequential mFOLFOX6 then FOLFIRI, each with bevacizumab | Progression-free survival 2 of 19.2 against 16.4 months (hazard ratio 0.74). | |
TRIBE NCT00719797 | 3 | Positive | Untreated metastatic colorectal cancer: FOLFOXIRI plus bevacizumab against FOLFIRI plus bevacizumab | Progression-free survival 12.1 against 9.7 months (hazard ratio 0.75); response rate 65 against 53 percent. | |
| 3 | Planned | Adjuvant Modified FOLFOXIRI Versus mFOLFOX6 in Patients With Postoperative MRD Positive Stage II-III Colorectal Cancer: A Multicenter, Open Lable Randomized Phase 3 Study (AFFORD) | - | ||
| 3 | Planned | MEND-IT II: Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy, Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer. | - | ||
| 3 | Recruiting | Neoadjuvant FOLFOXIRI Chemotherapy Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer: An Open Label Randomized Controlled Phase III Trial | - | ||
| 3 | Recruiting | Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer Prospective, Randomized, Open, Multicenter Phase III Trial to Investigate the Efficacy of Active Post-resection/Ablation Therapy in Patients With Metastatic Colorectal Cancer | - | ||
| 3 | Planned | Pre-Operative Treatment in REseCTable COlon CanceR (PROTECTOR/FIRE-10; AIO-KRK-0620; IAG-VO-0323) Prospective, Randomized, Open, Multicenter Phase III Trial to Investigate the Efficacy Preoperative Systemic Therapy in Advanced Colon Cancer | - | ||
| 3 | Recruiting | Prospectively Randomized Control Clinical Trial of FOLFOXIRI Preoperative Chemotherapy Alone on Rectal Cancer in Local Advance Comparing to Oral Capecitabine Combined With Long-term Radiation | - | ||
| 2 | Planned | A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation | - | ||
| 2 | Recruiting | Value of CtDNA in Surveillance of Adjuvant Chemosensitivity and Regimen Adjustment in Stage III Colon Cancer: a Phase II Randomized Controlled Trial (REVISE Trial) | - | ||
| 2 | Planned | Neoadjuvant mFOLFOXIRI Plus Bevacizumab for Organ Preservation in Locally Advanced Rectal Cancer: A Singe-arm Phase II Study | - | ||
| 2 | Recruiting | Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 Alone in Locally Advanced Colorectal Cancer: a Randomized Control Phase II Study (OPTICAL-2) | - |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"UGT1A1" OR ABSTRACT:"UGT1A1" OR TITLE:"UDP glucuronosyltransferase family 1 member A1" OR ABSTRACT:"UDP glucuronosyltransferase family 1 member A1" OR TITLE:"UDP-glucuronosyltransferase 1A1" OR ABSTRACT:"UDP-glucuronosyltransferase 1A1" OR TITLE:"UGT1A" OR ABSTRACT:"UGT1A" OR TITLE:"UGT1" OR ABSTRACT:"UGT1" OR TITLE:"GNT1" OR ABSTRACT:"GNT1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about UGT1A1, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/ugt1a1.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/ugt1a1.json. Licence CC BY-NC 4.0.